In both the United States and other parts of the world, kidney stones are becoming an increasingly regular occurrence. There is a correlation between type 2 diabetes and an increased risk of kidney stones; however, there are a variety of treatment options available for this condition that have the ability to minimize the risk of kidney stones formation.
The use of sodium-glucose contratransporter 2 (SGLT2) inhibitors was found to be connected with a reduced risk of developing kidney stones, according to the findings of researchers at Mass General Brigham. Their results were later reported in the journal JAMA Internal Medicine.
The investigation was carried out by researchers from Massachusetts General Hospital and Brigham and Women’s Hospital working together to undertake the investigation. The research incorporated information obtained from three national databases pertaining to individuals diagnosed with type 2 diabetes who were seen in the course of their regular clinical practice. In their study, the researchers looked at information from 716,406 people who had type 2 diabetes and had started taking either an SGLT2 inhibitor or one of two additional types of diabetes medications known as GLP1 receptor agonists or dipeptidyl peptidase 4 (DPP4) inhibitors.
In comparison to patients who were using GLP1 agonists, those who started taking SGLT2 inhibitors had a thirty percent lower risk of developing kidney stones, and those who started taking DPP4 inhibitors had a twenty-five percent lower risk altogether. The findings were constant regardless of factors such as gender, race or ethnicity, a previous history of chronic renal illness, or obesity.
“Our findings could help inform clinical decision making for patients with diabetes who are at risk of developing kidney stones,” said corresponding author Julie Paik, MD, ScD, MPH, of Brigham and Women’s Hospital’s Divisions of Pharmacoepidemiology and Pharmacoeconomics and Renal (Kidney) Medicine.
For more information: Sodium-Glucose Cotransporter 2 Inhibitors and Nephrolithiasis Risk in Patients With Type 2 Diabetes, JAMA Internal Medicine (2024). DOI: 10.1001/jamainternmed.2023.7660
more recommended stories
Lipid Accumulation Product Predicts Bone LossA new study reveals that lipid.
AI-Designed COVID Vaccine AntigensAs SARS-CoV-2 continues to evolve, existing.
Multi-Cancer Early Detection Test Saves LivesA groundbreaking multi-cancer early detection test.
Breath Sensor for Chronic Kidney Disease DetectionIn a groundbreaking development, researchers have.
Vagus Nerve Stimulation for PTSD ReliefA pioneering clinical study from The.
Gut Microbiota Diet Score and Infertility: Surprising Link RevealedCan what you eat really impact.
Lung Cancer Outcomes Linked to PSG Genes in WomenResearchers at Memorial Sloan Kettering Cancer.
Osteoarthritis Genetic Targets Identified in Largest StudyIn a groundbreaking achievement, researchers have.
lncRNAs in Tumor Microenvironment Drive Cancer ProgressionThe tumor microenvironment (TME) is a.
Lyme Disease Symptoms: Why They Linger After TreatmentLyme disease symptoms that persist after.
Leave a Comment